Assessment of damage in Takayasu‘s arteritis

Tahra, Sema Kaymaz; Alıbaz-Öner, Fatma; Direşkeneli, Haner

doi:10.1016/j.semarthrit.2020.04.003

Cited by 13 publications

(10 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…We have previously shown that higher damage scores were associated with higher cumulative GC doses in patients with TAK. 17,18 Our results in the present study showed that MetS was another factor affecting the vascular damage score in TAK. Similar to our results, Demir et al found that presence of MetS was associated with higher SLE disease damage scores.…”

Section: Discussionsupporting

confidence: 56%

Metabolic syndrome is associated with increased cardiovascular risk and disease damage in patients with Takayasu arteritis

et al. 2022

Self Cite

View full text Add to dashboard Cite

Objective: Metabolic syndrome (MetS) is one of the preventable risk factors for cardiovascular disease (CVD). The aim of this study was to investigate the effect of MetS on CVD and cumulative organ damage in a multi-center, large cohort of patients with Takayasu arteritis (TAK).Methods: This is a cross-sectional study involving 192 consecutive TAK patients from seven tertiary rheumatology centers in Turkey. Clinical data of TAK patients fulfilling the 1990 American College of Rheumatology classification criteria were collected from medical records. They were evaluated for risk factors of CVD, disease activity, damage, and MetS at their last visits.Results: A total of 192 consecutive TAK patients were included in this study. One hundred and fifty-eight (82%) were female, the mean age was 43.3 ± 13 years, and mean disease duration was 13.5 ± 9.3 years. MetS was detected in 50 (26%) of the patients and CVD was detected in 28 (14.6%). The presence of MetS was detected as an independent risk factor for CVD (P < 0.001). In addition, the mean vasculitis damage index of the group with MetS was significantly higher than in the other patients (4.5 ± 3.3 vs 3.2 ± 2.2, respectively, P = 0.004). Conclusion:The presence of MetS in TAK is associated with increased CVD and disease damage. Awareness and management of MetS can improve disease prognosis in patients with TAK.

show abstract

Section: Discussionsupporting

confidence: 56%

Metabolic syndrome is associated with increased cardiovascular risk and disease damage in patients with Takayasu arteritis

et al. 2022

Self Cite

View full text Add to dashboard Cite

show abstract

“…Vasculitis-associated damage was evaluated using TADS 10 and VDI 11 . TADS captures TAK-specific vascular damage, whereas VDI is applied to all types of systemic vasculitides 9 , 12 . TADS and VDI were measured at the last visit before November 2020.…”

Section: Methodsmentioning

confidence: 99%

“…Damage to systemic vasculitides is defined as irreversible scars in the involved organs, which may be caused by either disease activity or therapeutic approaches 9 . The damage measures for TAK, such as the Takayasu arteritis damage score (TADS) 10 and Vasculitis Damage Index (VDI) have been developed 11 .…”

Section: Introductionmentioning

confidence: 99%

“…The damage measures for TAK, such as the Takayasu arteritis damage score (TADS) 10 and Vasculitis Damage Index (VDI) have been developed 11 . The former is a TAK-specific damage measure focusing mainly on disease-related damage in the cardiovascular system, whereas the latter is a validated damage score for use in all types of systemic vasculitides, which also captures treatment-related damage well 9 , 12 . In addition, as an imaging-based scoring system to evaluate systemic angiographic damages in large vessel vasculitis, Arteritis Stenosis Score (ASS), Arteritis Dilation Score (ADS), and Arteritis Composite Score (ACS) have been developed and validated 13 .…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

A susceptibility locus in the IL12B but not LILRA3 region is associated with vascular damage in Takayasu arteritis

Kadoba

Watanabe

Iwasaki

et al. 2021

Sci Rep

View full text Add to dashboard Cite

HLA-B*52 is an established genetic factor in Takayasu arteritis (TAK). Recently, single nucleotide polymorphisms (SNPs) in IL12B (rs6871626) and LILRA3 (rs103294) were newly identified as non-HLA susceptibility loci in TAK. Here, we examined how these SNPs contribute to clinical characteristics and vascular damage in TAK. We retrospectively reviewed the medical records of 99 TAK patients enrolled in our previous genome-wide association study, and whose genotypes for IL12B rs6871626, LILRA3 rs103294, and HLA-B*52 were available. Incidence of aortic regurgitation (AR) was significantly associated with the A allele (risk allele) of IL12B rs6871626 (CC 42%, AC 61%, AA 81%; p = 0.0052; odds ratio [OR] 2.45), as well as with the incidence of hypertension (p = 0.049; OR 1.82) and the proportion of patients who underwent aortic valve replacement (p = 0.023; OR 3.64). Regarding vascular damage, there was positive correlation between the Takayasu Arteritis Damage Score and the A allele of IL12B rs6871626 (CC 3.42 ± 2.71, AC 4.06 ± 3.25, AA 6.00 ± 2.81; p = 0.0035; β = 1.35) and between the Vasculitis Damage Index and the A allele (CC 3.47 ± 1.98, AC 4.33 ± 2.40, AA 5.37 ± 2.22; p = 0.0054; β = 0.96). Contrarily, no correlation was found between LILRA3 rs103294 and vascular damage. In the present study, IL12B rs6871626 was associated with vascular damage in TAK, whereas LILRA3 rs103294 was not. Genotyping of IL12B rs6871626 may help to identify patients at risk of disease progression.

show abstract

“…One of the main challenges in assessing TA is distinguishing damage from disease activity to prevent unnecessary use of cytotoxic medication for newly detected irreversible vascular lesions [15]. Diverse scoring systems have been used to assess damage in TA, such as Vasculitis Damage Index (VDI) and Takayasu Arteritis Damage Score (TADS).…”

Section: Introductionmentioning

confidence: 99%

Enhanced Liver Fibrosis Score as a Biomarker for Vascular Damage Assessment in Patients with Takayasu Arteritis—A Pilot Study

Stojanović

Rašković

Milivojević

et al. 2021

JCDD

View full text Add to dashboard Cite

Takayasu arteritis (TA) is characterized by granulomatous panarteritis, vessel wall fibrosis, and irreversible vascular impairment. The aim of this study is to explore the usefulness of the Enhanced Liver Fibrosis score (ELF), procollagen-III aminoterminal propeptide (PIIINP), tissue inhibitor of matrix metalloproteinase-1 (TIMP-1), and hyaluronic acid (HA) in assessing vascular damage in TA patients. ELF, PIIINP, TIMP-1, and HA were measured in 24 TA patients, and the results were correlated with the clinical damage indexes (VDI and TADS), an imaging damage score (CARDS), and disease activity scores (NIH and ITAS2010). A mean ELF score 8.42 (±1.12) and values higher than 7.7 (cut-off for liver fibrosis) in 21/24 (87.5%) of patients were detected. The VDI and TADS correlated significantly to ELF (p < 0.01). Additionally, a strong association across ELF and CARDS (p < 0.0001), PIIINP and CARDS (p < 0.001), and HA and CARDS (p < 0.001) was observed. No correlations of the tested biomarkers with inflammatory parameters, NIH, and ITAS2010 scores were found. To our knowledge, this is the first study that suggests the association of the serum biomarkers PIIINP, HA, and ELF score with damage but not with disease activity in TA patients. The ELF score and PIIINP may be useful biomarkers reflecting an ongoing fibrotic process and quantifying vascular damage.

show abstract

Assessment of damage in Takayasu‘s arteritis

Cited by 13 publications

References 32 publications

Metabolic syndrome is associated with increased cardiovascular risk and disease damage in patients with Takayasu arteritis

Metabolic syndrome is associated with increased cardiovascular risk and disease damage in patients with Takayasu arteritis

A susceptibility locus in the IL12B but not LILRA3 region is associated with vascular damage in Takayasu arteritis

Enhanced Liver Fibrosis Score as a Biomarker for Vascular Damage Assessment in Patients with Takayasu Arteritis—A Pilot Study

Contact Info

Product

Resources

About